Quest Diagnostics Incorporated DGX on Tuesday reported first-quarter adjusted earnings of $2.50 per share, beating the ...

Quest Diagnostics bucked concerns Tuesday that storms would wash out its first-quarter report. The stock jumped on a beat and raise.

(DGX) downgraded to a Hedgeye short with 20% downside risk as growth decelerates and valuation stays elevated.

Quest Diagnostics is back in focus after a slight trim to its modeled fair value, with the price target adjusted to $218.19 from $218.50, a change of about 0.1%. That small move comes alongside a mix ...

DGX posts Q1 2026 earnings and revenue beat, with adjusted EPS up 13% and shares rising in pre-market trading.

By Sahil Pandey April 21 (Reuters) - Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient ...

Detailed price information for Quest Diagnostics Inc (DGX-N) from The Globe and Mail including charting and trades.

Q1 2026 earnings call recap: 9% organic growth, raised revenue/EPS guidance, Corewell/Fresenius mix, AI traction & PAMA ...

A Secaucus office tower has surpassed 75% occupancy after three lease agreements totaling 145,000 square feet were signed in ...

Irvine-based Helio Genomics announces partnership with Quest Diagnostics to distribute its liver cancer detection test ...

On Tuesday, Quest Diagnostics Incorporated (NYSE:DGX) reported first quarter results that exceeded analyst expectations and ...

For both the three months ended March 31, 2026 and 2025, the pre-tax impact represents costs primarily associated with ...